Results 101 to 110 of about 31,169 (238)
ASYMPTOMATIC CHOLELITHIASIS, POLYCYTHEMIA AND HYPERBILIRUBINEMIA [PDF]
Gall stone or cholelithiasis is a common gastrointestinal problem. It is usually related to hyperlipidemia or hemolytic anemia. Here, the author presents an interesting case of asymptomatic cholelithiasis seen in patient with polycythemia and has ...
WIWANITKIT, VIROJ
core
Chronic Diseases and Translational Medicine, Volume 12, Issue 3, Page 183-196, September 2026.Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig +7 more
wiley +1 more source
Rare gallbladder parasitosis mimicking cholelithiasis: Dicrocoelium dendriticum
, 2008 Choleithiasis is increasingly diagnosed in childhood and infancy. Biliary parasites are the rarest cause of cholelithiasis in all age groups. We present a twelve-year-old girl with non-hemolytic gallbladder stone and discuss the clinical features and ...
KUL, OĞUZ +6 more
core +2 more sources
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.In this multicentre real‐world post‐marketing surveillance (rPMS) study conducted in Taiwan, reductions in body weight and no new safety issues were observed among adults with obesity treated with liraglutide. ABSTRACT Introduction This prospective study (NCT06283641) was the first real‐world, multicentre, post‐marketing surveillance of GLP‐1 receptor ...
Shih‐Te Tu +15 more
wiley +1 more source
Cholelithiasis ascomorbidity polycystic ovary syndrome disease [PDF]
Гинекология, 2015 Polycystic ovary syndrome (PCOS) is a complex interdisciplinary problem in connection with the involvement in the pathogenesis not only of reproductive system, but also multifaceted metabolic disorders, many of which are pathognomonic for cholelithiasis.
Yu B Uspenskaya, I V Kuznetsova
doaj
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.The comparative pharmacology and cardiometabolic outcomes of semaglutide, liraglutide and tirzepatide, integrating evidence from major clinical trial programs and meta‐analyses. ABSTRACT Background Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges.
Hiba Bawadi +4 more
wiley +1 more source
The epidemiology of gallstone disease in Rome, Italy. Part I: prevalence data in men
, 1988 A population of male civil servants in Rome, Italy, was investigated to determine the prevalence of symptomatic and asymptomatic gallstone disease. Field activities started in December, 1982 and were concluded in July, 1984. Diagnosis was made using real-
ARCA, Marcello +2 more
core
Management of Refractory and Difficult‐To‐Treat Inflammatory Bowel Disease: An Expert Opinion Review
JCC Plus, Volume 1, Issue 5, September 2026.This expert opinion offers a practical framework for refractory and difficult‐to‐treat IBD: confirm inflammation objectively, distinguish pharmacologic from structural and functional disease, and then escalate. Across ten clinical questions, the evidence is often limited to case series, and the resulting statements are identified as expert opinion ...
Filiz Akyuz +10 more
wiley +1 more source
Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study
Hao Dong,1,* Rong Chen,2,* Fang Xu,3,* Fang Cheng4 1Department of Gastroenterology and Hepatology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China; 2Department of Rehabilitation Medicine ...
Cheng F, Dong H, Xu F, Chen R
core
The Evolution of Medications for Obesity Management
JGH Open, Volume 10, Issue 9, September 2026.ABSTRACT This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns.
Jaskirath Gill, Priya Sumithran
wiley +1 more source